Relay Therapeutics (RLAY) News Today $5.11 -0.49 (-8.76%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8% - Time to Sell?Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.8% - Here's WhyNovember 15 at 1:13 PM | marketbeat.comFY2024 Earnings Forecast for RLAY Issued By Leerink PartnrsNovember 13, 2024 | americanbankingnews.comFY2024 Earnings Estimate for RLAY Issued By Leerink PartnrsRelay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Investment analysts at Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for shares of Relay Therapeutics in a report released on Wednesday, November 6th. Leerink Partnrs analyst A. Berens now forecasts that the company wiNovember 11, 2024 | marketbeat.comHC Wainwright Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $20.00HC Wainwright lifted their price objective on shares of Relay Therapeutics from $19.00 to $20.00 and gave the company a "buy" rating in a research note on Friday.November 8, 2024 | marketbeat.comPromising Pipeline and Financial Stability Drive Buy Rating for Relay TherapeuticsNovember 8, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Relay Therapeutics (RLAY)November 7, 2024 | markets.businessinsider.comBuy Rating on Relay Therapeutics: Promising Developments and Strong Financial PositionNovember 7, 2024 | markets.businessinsider.comRelay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate HighlightsNovember 6, 2024 | globenewswire.comRelay Therapeutics (RLAY) Scheduled to Post Earnings on WednesdayRelay Therapeutics (NASDAQ:RLAY) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 6,802 SharesOctober 31, 2024 | insidertrades.comRelay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024October 30, 2024 | globenewswire.comInstitutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term lossesOctober 28, 2024 | finance.yahoo.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of "Moderate Buy" from AnalystsShares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have earned an average rating of "Moderate Buy" from the ten analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and nine have issued a buy rating onOctober 28, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest UpdateRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totalling 12,370,000 shares, an increase of 24.7% from the September 15th total of 9,920,000 shares. Based on an average trading volume of 1,910,000 shares, the days-to-cover ratio is currently 6.5 days.October 15, 2024 | marketbeat.comBuy Rating for Relay Therapeutics: Promising Pipeline and Positive PI3Ka Inhibitor ProspectsOctober 15, 2024 | markets.businessinsider.comRelay Therapeutics (NASDAQ:RLAY) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $19.00 target price on shares of Relay Therapeutics in a research note on Monday.October 14, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading Volume - Still a Buy?Relay Therapeutics (NASDAQ:RLAY) Sees Strong Trading Volume - Still a Buy?October 11, 2024 | marketbeat.comMillennium Management LLC Acquires 921,271 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Millennium Management LLC grew its position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 404.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,149,177 shares of the company's stock after buying an additional 921,271October 10, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 4% - Here's WhyRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 4% - Time to Sell?October 9, 2024 | marketbeat.comThrivent Financial for Lutherans Acquires Shares of 120,011 Relay Therapeutics, Inc. (NASDAQ:RLAY)Thrivent Financial for Lutherans acquired a new stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 120,011 shares of the company's stock, valued at apOctober 8, 2024 | marketbeat.com144,986 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Acquired by Squarepoint Ops LLCSquarepoint Ops LLC purchased a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 144,986 shares of the company's stock, valued at approximately $October 7, 2024 | marketbeat.comMarshall Wace LLP Purchases New Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)Marshall Wace LLP acquired a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 276,702 shares of the company's stock, valued atOctober 6, 2024 | marketbeat.comRelay Therapeutics cuts 10% of staff after positive trial dataOctober 4, 2024 | bizjournals.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy raOctober 3, 2024 | marketbeat.comAlgert Global LLC Purchases 174,953 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Algert Global LLC raised its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 57.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 476,888 shares of the company's stock afOctober 2, 2024 | marketbeat.comRelay Therapeutics Target of Unusually Large Options Trading (NASDAQ:RLAY)Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Investors purchased 20,044 put options on the stock. This represents an increase of 6,366% compared to the average daily volume of 310 put options.October 1, 2024 | marketbeat.comDriehaus Capital Management LLC Purchases 218,302 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Driehaus Capital Management LLC grew its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 54.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 616,220 shares of the company's stock after acquiring an additional 218,September 30, 2024 | marketbeat.comRenaissance Technologies LLC Raises Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)Renaissance Technologies LLC boosted its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 19.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 909,037 shares of the company's stock after pSeptember 27, 2024 | marketbeat.comRelay Therapeutics (RLAY) Receives a Buy from BarclaysSeptember 25, 2024 | markets.businessinsider.comLogos Global Management LP Acquires New Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY)Logos Global Management LP acquired a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,300,000 shares of the company's stock, valued atSeptember 24, 2024 | marketbeat.comRelay Therapeutics: A Buy Rating on Robust RLY-2608 Performance and Strategic Trial DesignSeptember 18, 2024 | markets.businessinsider.comRelay Therapeutics (NASDAQ:RLAY) Given "Market Outperform" Rating at JMP SecuritiesJMP Securities reissued a "market outperform" rating and set a $21.00 target price on shares of Relay Therapeutics in a research note on Tuesday.September 17, 2024 | marketbeat.comMarket Outperform: Relay Therapeutics Leads with Promising PI3K Inhibitor in Competitive Oncology SpaceSeptember 17, 2024 | markets.businessinsider.comRelay up 5% as Street applauds breast cancer candidate dataSeptember 16, 2024 | msn.comRelay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards ExpansionSeptember 16, 2024 | seekingalpha.comBuy Rating Affirmed for Relay Therapeutics Amid Promising Clinical Outcomes and Strategic Market PositioningSeptember 16, 2024 | markets.businessinsider.comRelay Therapeutics (NASDAQ:RLAY) Shares Gap Up After Analyst UpgradeRelay Therapeutics (NASDAQ:RLAY) Shares Gap Up After Analyst UpgradeSeptember 16, 2024 | marketbeat.comStifel Nicolaus Reaffirms "Buy" Rating for Relay Therapeutics (NASDAQ:RLAY)Stifel Nicolaus restated a "buy" rating and set a $28.00 price target on shares of Relay Therapeutics in a research report on Monday.September 16, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Price Target Raised to $19.00 at HC WainwrightHC Wainwright lifted their price target on Relay Therapeutics from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Monday.September 16, 2024 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Stock Holdings Decreased by TD Asset Management IncTD Asset Management Inc lessened its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 42.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 206,056 shares of the company's stock after selling 152,600 sSeptember 15, 2024 | marketbeat.comLos Angeles Capital Management LLC Purchases 92,230 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Los Angeles Capital Management LLC grew its position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 661.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 106,169 shares of the company's stock after bSeptember 14, 2024 | marketbeat.comRelay Therapeutics’ RLY-2608 Shows Superior Efficacy in Breast Cancer Trial, Merits Buy RatingSeptember 13, 2024 | markets.businessinsider.comQ3 2024 EPS Estimates for Relay Therapeutics, Inc. (NASDAQ:RLAY) Lifted by AnalystRelay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Equities researchers at Leerink Partnrs upped their Q3 2024 earnings per share (EPS) estimates for shares of Relay Therapeutics in a research report issued on Tuesday, September 10th. Leerink Partnrs analyst A. Berens now anticipates that theSeptember 13, 2024 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 4.4% Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.4%September 12, 2024 | marketbeat.comRelay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα MutationsSeptember 12, 2024 | seekingalpha.comWhy Relay Therapeutics (RLAY) Stock Is Down 17% TodaySeptember 12, 2024 | msn.comWhy Relay Therapeutics Plummeted by Nearly 14% TodaySeptember 11, 2024 | fool.comRelay Therapeutics’ RLY-2608 Shows Promising Efficacy and Safety, Earning a Buy RatingSeptember 11, 2024 | markets.businessinsider.comRelay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor MarketSeptember 11, 2024 | msn.comRelay upgraded by Jefferies, downgraded by OppenheimerSeptember 11, 2024 | seekingalpha.com Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics… Get Your Free Gold Guide RLAY Media Mentions By Week RLAY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLAY News Sentiment▼0.920.55▲Average Medical News Sentiment RLAY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLAY Articles This Week▼73▲RLAY Articles Average Week Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALLO News VIR News FATE News VRNA News HCM News ACAD News DYN News ZLAB News AMRX News MOR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLAY) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLAY Stock Alerts